Correction

This article refers to:

Anti-IL 23 biologics for the treatment of plaque psoriasis

Article title: Anti-IL 23 biologics for the treatment of plaque psoriasis

Authors: Vu, A., Ulschmid, C., & Gordon, K. B.

Journal: EXPERT OPINION ON BIOLOGICAL THERAPY

DOI: https://doi.org/10.1080/14712598.2022.2132143

When this article was first published, Tables 1 and Table 2 contained incorrect information regarding the approval for use of risankizumab and guselkumab in psoriatic arthritis (PsA). The following changes have been made to correct this:

Table 1. Current Biologic Therapies for Moderate-to Severe-Psoriasis

Drug	Inhibitor Target	NCT#	N (Study Name)	Primary Endpoint	Efficacy at Primary Endpoint^a	FDA Approval	Adult Dosing^b	Average Time to Response	PsAApproval	Ref
Etanercept	TNF-α		1187	PASI 75 at Week 12	49% (50 mg BIW) 33% (25 mg BIW)	2004	Initial: 50 mg SQ BIW for 3 months Maintenance:50 mg SQ QW	12-16 weeks	Yes	[1,13,14]
Infliximab	TNF-α		835	PASI 75 at Week 10	75.5% (5 mg/kg) 70.3% (3 mg/kg)	2006	Initial: 5 mg/kg IV at Weeks 0/2/6 Maintenance:5 mg/kg IV Q8W	8-10 weeks	Yes	[1,15,16]
Adalimumab	TNF-α	NCT00237887	1212 (REVEAL)	PASI 75 at Week 16	71%	2008	Initial: 80 mg SQ once Maintenance: 40 mg SQ QOW starting Week 1	12-16 weeks	Yes	[1,17,18]
Certolizumab	TNF-α	NCT02346240	559 (CIMPACT)	PASI 75 at Week 12	61.3% (200 mg) 66.7% (400 mg)	2018	Wt>90 kg: 400 mg SQ QOW Wt ≤90 kg: 400 mg Weeks 0/2/4, then 200 mg QOW	12-16 weeks	Yes	[1,19,20]
Secukinumab	IL-17A	NCT01365455	738 (ERASURE)	PASI 75 at Week 12	81.6% (300 mg; ERASURE) 71.6% (150 mg; ERASURE)	2015	Initial: 300 mg SQ QW for 4 weeks Maintenance:300 mg SQ Q4W (some patients may use 150 mg per dose)Alternate (no loading dose): 150 mg SQ Q4W	12 weeks	Yes	[1,21,22]
		NCT01358578	1306 (FIXTURE)		77.1% (300 mg; FIXTURE) 67.0% (150 mg; FIXTURE)
Ixekizumab	IL-17A	NCT01597245	1224 (UNCOVER-2)	PASI 75 at Week 12	77.5% (Q4W; UNCOVER-2) 89.7% (Q2W; UNCOVER-2)	2016	Initial: 160 mg SQ Week 0, 80 mg SQ Q2W for 12 weeks Maintenance: 80 mg SQ Q4W	12 weeks	Yes	[1,23,24]
		NCT01646177	1346 (UNCOVER-3)		84.2% (Q4W; UNCOVER-3) 87.3% (Q2W; UNCOVER-3)
Brodalumab	IL-17A Receptor	NCT01708603	1776 (AMAGINE-2)	PASI 75 at Week 12	86% (210 mg; AMAGINE-2) 67% (140 mg; A MAGINE-2)	2017	Initial: 210 mg SQ Week 0/1/2 Maintenance: 210 mg SQ QOW	12 weeks	No	[1,25,26]
		NCT1708629	1816 (AMAGINE-3)		85% (210 mg; AMAGINE-3) 69% (140 mg; AMAGINE-3)
Ustekinumab	IL-12 & IL-23	NCT00267969	766 (PHOENIX 1)	PASI 75 at Week 12	67.1% (45 mg; PHOENIX 1) 66.4% (90 mg; PHOENIX 1)	2009	Wt>100 kg: 90 mg SQ Weeks 0/4, then 90 mg SQ Q12WWt≤100 kg: 45 mg SQ Weeks 0/4, then 45 mg SQ Q12W	12 weeks	Yes	[1,27-32]
		NCT00307437	1230(PHOENIX 2)		66.7% (45 mg; PHOENIX 2) 75.7% (90 mg; PHOENIX 2)
Guselkumab	Il-23	NCT02207231	837 (VOYAGE-1)	PASI 90 at Week 16	73.3% (VOYAGE-1)	2017	Initial: 100 mg SQ Weeks 0/4 Maintenance: 100 mg SQ Q8W	12 weeks	Yes	[1,33-35]
		NCT02207244	992 (VOYAGE-2)		70.0% (VOYAGE-2)
Tildrakizumab	IL-23	NCT01722331	772 (reSURFACE 1)	PASI 75 at Week 12	64% (100 mg; reSURFACE1) 62% (200 mg; reSURFACE1)	2018	Initial: 100 mg SQ Weeks 0/4 Maintenance: 100 mg SQ Q12W	12 weeks	No	[1,36-38]
		NCT01728754	1090 (reSURFACE 2)		61% (100 mg; reSURFACE2) 66% (200 mg; reSURFACE2)
Risankizumab	IL-23	NCT02684370	506 (UltIMMa-1)	PASI 90 and sPGA 0/1 at Week 16	75.3% and 87.8% (UltIMMa-1))	2019	Initial: 150 mg SQ Weeks 0/4 Maintenance: 150 mg SQ Q12W	12 weeks	Yes	[1,39-44]
		NCT02684357	491 (UltIMMa-2)		74.8% and 83.7% (UltIMMa-2)
		NCT02672852	507 (IMMhance)		73.2% and 83.5% (IMMhance)
		NCT02694523	684 (IMMvent)		72% and 84%(IMMvent)

^aFormatted by: efficacy% (cohort; Clinical Trial name, if available)

^bAdult dosing for use in moderate-to-severe plaque psoriasisNCT# - ClinicalTrials.gov identifier number; N - number of subjects; FDA - US Food and Drug Administration; PsA - psoriatic arthritis; TNF-α - Tumor Necrosis Factor-α; PASI (n) - n% improvement in the Psoriasis Area and Severity Index; SQ - subcutaneously; BIW - twice weekly; QW - once weekly; QOW - every other week; IL - interleukin; Q(n)W - every nth week; Wt – weight; sPGA 0/1 – static Physician’s Global Assessment score of 0 or 1

Table 2. Current IL-23 Inhibitor Therapies for Moderate-to-Severe Psoriasis

Drug	Inhibitor Target	FDA Approval^a	EMA Approval^a	Adult Dosing^b	Average Time to Response^c	Time to Peak^c	Half-life elimination^c	Pediatric Approval^d	Pediatric Dosing^d	PsA Approval	Ref
Ustekinumab	IL-12 & IL-23 p40 subunit	2009	2009	Wt>100 kg: 90 mg SQ Weeks 0/4, then 90 mg SQ Q12WWt≤100 kg: 45 mg SQ Weeks 0/4, then 45 mg SQ Q12W	12 weeks	13.5 days(45 mg)7 days (90 mg)	15-46 days	Yes^e	Administered Weeks 0 and 4, then every 12 weeks thereafter:• Wt< 60 kg: 0.75 mg/kg• Wt ≥ 60 kg and ≤ 100 kg: 45 mg• Wt > 100 kg: 90 mg	Yes^f	[1,27-32,51,52]
Guselkumab	Il-23 p19 subunit	2017	2017	Initial: 100 mg SQ Weeks 0/4Maintenance: 100 mg SQ Q8W	12 weeks	5.5 days	15-18 days	No	n/a	Yes^g	[1,23-25]
Tildrakizumab	Il-23 p19 subunit	2018	2018	Initial: 100 mg SQ Weeks 0/4Maintenance: 100 mg SQ Q12W	12 weeks	6 days	23 days	No	n/a	No	[1,33-35]
Risankizumab	Il-23 p19 subunit	2019	2019	Initial: 150 mg SQ Weeks 0/4Maintenance: 150 mg SQ Q12W	12 weeks	3-14 days	28-29 days	No	n/a	Yes^g	[1,44-49]

^aApproval from the respective institutions for the purpose of moderate-to-severe plaque psoriasis in adult patients.

^bAdult dosing for use in moderate-to-severe plaque psoriasis

^cPharmacokinetic data listed represents data for the adult plaque psoriasis patient population.

^dPediatric dosing for use in moderate-to-severe plaque psoriasis. Dosing organized by administration schedule followed by weight-based dosing instructions.

^eUstekinumab has been approved by the EMA in 2020 and FDA in 2022 for pediatric patients age 6 years or older for moderate-to-severe plaque psoriasis.

^fPsoriatic arthritis indication for ustekinumab is for adults only by the EMA and adults and children 6 years or older by the FDA as of 2022.

^gRisankizumab and guselkumab have been approved for the treatment of psoriatic arthritis in adult patients by both the FDA and EMA as of 2022.FDA - US Food and Drug Administration; EMA - European Medicines Agency; PsA - psoriatic arthritis; IL - interleukin; SQ - subcutaneously; Wt – weight; Q(n)W - every nth week; Adult and pediatric dosing, time to peak, and half-life elimination data obtained from the European public assessment reports and FDA-approved labels for the respective medications.

In table 1, PsA Approval has been changed from No to Yes for both guselkumab and risankizumab.

In table 2, PsA Approval has been changed from No to Yes for both guselkumab and risankizumab. An additional footnote (g) has been added that states “Risankizumab and guselkumab have been approved for the treatment of psoriatic arthritis in adult patients by both the FDA and EMA as of 2022.”